ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 111 citations in OpenAlex.
- In situ Gel-Nano transformable hydrogel for therapeutic intervention in refractory inflammation-related trauma.Materials today. Bio · 2026Article
- Illuminating cancer therapy: The translational path of optogenetics.Bioactive materials · 2026Review
- A Peritoneum-Inspired Biomimetic Asymmetric Patch for Functional Repair and Anti-Adhesion in Abdominal Wall Defects.Advanced healthcare materials · 2026Article
- Advances in Polydopamine-Based Nanoplatforms: Antioxidant Mechanisms and Applications in Oxidative Stress-Mediated Diseases.Nano-micro letters · 2026Review
- Photo- and Immunotherapy Interface: Can Dendritic Cell Vaccines Overcome the Limitations of PDT?Pharmaceutics · 2026Review
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- Gut microbiota signatures and predictive model of KPS in advanced colorectal cancer patients.Gut pathogens · 2026Article
- An Injectable Hybrid Gelatin Methacryloyl/Polydopamine Nanoparticle Bioink for Rapid Hemostasis Applications.ACS applied bio materials · 2026Article
- Stress-trained microalgae robots with probiotics backpack and intestinal brake for inflammatory bowel disease management.Nature communications · 2026Article
- The challenges and strategies for navigatingTheranostics · 2026Review
- Polydopamine nanoparticles restore cognition via targeted dopamine delivery and septo-hippocampal cholinergic activation.Theranostics · 2026Article
- Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.Small science · 2026Review
- Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.Journal of hematology & oncology · 2025Review
- Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease.Materials today. Bio · 2025Review
- Polydopamine/chitosan layer-by-layer coating ofMaterials today. Bio · 2025Article
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Orally administered degradable nanoarmor-assisted probiotics for remodeling the gut microenvironment and treating osteoporosis.Journal of nanobiotechnology · 2025Article
- Generating theranostic bacteria by depositing a protective visual therapeutic nanocoating via in situ sequential mineralization.Science advances · 2025Article
- Positron Emission Tomography/Computed Tomography Imaging-Guided Polydopamine Nanoparticles Attenuate Foam Cell Ferroptosis for Targeted Antiatherosclerotic Therapy.Small science · 2025Article
- Emerging Understanding of Gut Microbiome in Colorectal Cancer and Food-Related Intervention Strategies.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Despite immunosuppression is critical for reducing immune overactivation, existing immunosuppressive agents are largely restricted by low inhibition efficiencies and unpredictable off-target toxicities. Here, the use of the dopaminergic system is reported to suppress hyperactive immune responses in local inflamed tissues. A polydopamine nanoparticular immunosuppressant (PDNI) is synthesized to stimulate regulatory T (Treg) cells and directly inhibit T helper 1 (Th1), Th2, and Th17 cells. Moreover, PDNI can inhibit the activation of dendritic cells to upregulate the ratio of Treg/Th17, which assists the reversion of inflammatory responses. The application of dopaminergic immunoregulation is further disclosed by combining with gut microbiota modulation for treating inflammations. The combination is implemented by coating living beneficial bacteria with PDNI. Following oral delivery, coated bacteria not only suppress the hyperactive immune responses but also positively modulate the gut microbiome in mice characterized with colitis. Strikingly, the combination demonstrates enhanced treatment efficacies in comparison with clinical aminosalicylic acid in two murine models of colitis. The use of the dopaminergic system opens a window to intervene immune responses and provides a versatile platform for the development of new therapeutics for treating inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.